-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although up to 30% of patients with non-small cell lung cancer can be diagnosed early for potential root-and-treatment surgery, recurrence is still common in early-stage diseases, with nearly half diagnosed as IB-phase NSCLC patients and more than three-quarters diagnosed as IIIA-phase NSCLC patients experiencing recurrence within five years.
This sNDA is based on the results of phase 3 clinical ADAURA trials, which showed improvements in disease-free survival (DFS) statistics and clinical significance in the primary analytical population of EGFRm NSCLC patients in Phase II and IIIA, as well as in the overall trial population of IB-IIIA phase NSCLC patients.
April 2020, the Independent Data Monitoring Board recommended that the trial be revealed two years in advance, based on the overwhelming efficacy of Oghidini in the postoperative assisted therapy trial for lung cancer (ADAURA).
researchers and patients continued to participate in the trial and remain blind to treatment; the results of the ADAURA trial were published in May at the annual meeting of the American Society of Clinical Oncology and recently published in the New England Journal of Medicine; and in July, Osimertinib, Tagrisso was recognized as a breakthrough therapy (BTD) in the United States.
is a third-generation, irreversible EGFR-TKI with clinical activity against central nervous system metastasis.
approved in the United States, Japan, China, the European Union and many other countries around the world for first-line treatment of localized advanced or metastasis EGFRm NSCLC patients.
it is worth mentioning that last week, the drug was included in the proposed priority review by china's National Drug Administration (NMPA) for complementary postoperative treatment of tumors in adult patients with EGFR-sensitive mutations.
resources: .1) Tagrisso granted Priority Review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. Retrieved 2020-10-20, from Source: Supplied
